Axsome Therapeutics, Inc.（AXSM）の株式分析AXSMAxsome Therapeutics, Inc.

Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Axsome Therapeutics Inc is currently not a strong buy due to its low RSI of 15.938, indicating oversold conditions, and a significant recent price drop of 7.70% over the last five days. However, the company's revenue growth is promising, with a 46% year-over-year increase to $218.4 million in Q2, driven by the strong performance of its drug Auvelity. The main risk is the widening net loss per share, which stands at -0.99, indicating ongoing financial challenges. Therefore, while there are positive growth indicators, the current technical and financial situation suggests holding rather than buying.

2 analysts cover AXSM: 2 rate it Buy, 0 Hold and 0 Sell. The average price target is 209.54.